» Articles » PMID: 16488330

What Have We Learned in Dermatology from the Biologic Therapies?

Overview
Specialty Dermatology
Date 2006 Feb 21
PMID 16488330
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Recent advances in our basic understanding of immunology, specifically the roles of various cell types involved in immune response and the action of cytokines they produce, has radically changed our understanding of the origin of inflammatory dermatoses, and other autoimmune diseases. Broadened comprehension of the immune response on a molecular level has facilitated the development of biologic therapeutics for the treatment of psoriasis, atopic dermatosis, and other inflammatory conditions. However, despite major advances in development and use of targeted biologics for controlling autoimmune disease, effective cures for these conditions remain to be developed and genetic determinants of predisposition to such diseases remain to be identified. Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area.

Citing Articles

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea.

Choi C, Yang S, Jo G, Kim B, Youn S Ann Dermatol. 2021; 30(6):668-675.

PMID: 33911506 PMC: 7992448. DOI: 10.5021/ad.2018.30.6.668.


Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis.

Choi C, Choi J, Kim B, Youn S Ann Dermatol. 2018; 30(2):179-185.

PMID: 29606815 PMC: 5839889. DOI: 10.5021/ad.2018.30.2.179.


Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.

Blauvelt A, Brown M, Gordon K, Kavanaugh A, Leonardi C, Stockfleth E J Clin Aesthet Dermatol. 2013; 6(9 Suppl):S2-S20.

PMID: 24167640 PMC: 3809592.


Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Brezinski E, Armstrong A PLoS One. 2012; 7(4):e33486.

PMID: 22509259 PMC: 3324468. DOI: 10.1371/journal.pone.0033486.


Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.

Zaba L, Suarez-Farinas M, Fuentes-Duculan J, Nograles K, Guttman-Yassky E, Cardinale I J Allergy Clin Immunol. 2009; 124(5):1022-10.e1-395.

PMID: 19895991 PMC: 2852188. DOI: 10.1016/j.jaci.2009.08.046.